Science for longer, healthier lives
Find a trial
About us

Science with a purpose

For 28 years, Calvera has turned discoveries into medicines for people with serious diseases.

Home/About
Our story

Started with one antibody. Built for the long run.

Calvera began in 1998 as a three-person lab with one antibody program. Today we discover and develop medicines across five therapeutic areas, with 16 medicines on the market and 24 programs in development.

We believe the best medicines come from deep biology, honest data and close partnership with patients and physicians. That is why we invest more than a fifth of our revenue back into research every year.

Patients firstEvery decision starts with the people who will take our medicines.
Rigorous scienceWe follow the evidence, publish our results and share our data.
One teamScientists, clinicians and operators working side by side.
Responsible growthLower emissions, fair pricing and access in 40+ countries.
Leadership

Executive team

EMElena MarshChief Executive Officer

Joined in 2016 to lead global commercial operations; CEO since 2021.

AOAmara Okafor, MD, PhDChief Scientific Officer

Former professor of medicine; leads discovery and translational research.

DLDavid LindqvistChief Financial Officer

Twenty years in healthcare finance and capital markets.

PRPriya Raman, MDChief Medical Officer

Oversees global clinical development and medical affairs.

MHMarcus HaleChief Operating Officer

Runs manufacturing, quality and supply across 11 sites.

SRSofia ReyesGeneral Counsel

Leads legal, compliance and patient privacy.

KWKenji Watanabe, PhDHead of Technical Operations

Built the company's gene therapy manufacturing network.

GWGrace WhitfieldChief People Officer

Focused on culture, talent and inclusion.

History

Milestones

  1. 1998Founded in Boston by three academic researchers with one antibody program.
  2. 2006First medicine approved: Moravel for major depressive disorder.
  3. 2012Initial public offering; expansion into immunology.
  4. 2017Acquired a gene therapy platform; Rare Disease unit formed.
  5. 2021Velorix approved; oncology becomes the largest therapeutic area.
  6. 2024Acquired Brightwater Neuro; revenue passes $15 billion.
  7. 2026New Raleigh research campus opens; 16 marketed medicines.
Locations

Where we work

Contact us →
Global Headquarters100 Harborview DriveBoston, MA 02210, USA+1 (555) 010-0100
Research Campus2500 Innovation WayRaleigh, NC 27606, USA+1 (555) 010-0200
European Headquarters18 Kingsgate SquareLondon EC2A 4BX, UK+44 20 5550 0300
Asia-Pacific Hub1-8-2 MarunouchiTokyo 100-0005, Japan+81 3 5550 0400